The stock of CytomX Therapeutics Inc (NASDAQ: CTMX) has increased by 3.45 when compared to last closing price of 2.03. Despite this, the company has experienced a -2.33% fall in its stock price over the last five trading sessions. InvestorPlace reported 2024-03-12 that CytomX Therapeutics (NASDAQ: CTMX ) stock is falling hard on Tuesday after the clinical-stage, oncology-focused biopharmaceutical company released its latest earnings report. The CytomX Therapeutics earnings report notes that the company spent most of 2023 cutting costs to continue operations.
Is It Worth Investing in CytomX Therapeutics Inc (NASDAQ: CTMX) Right Now?
The 36-month beta value for CTMX is also noteworthy at 1.03. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 3 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for CTMX is 66.41M, and at present, short sellers hold a 5.00% of that float. The average trading volume of CTMX on April 11, 2024 was 874.47K shares.
CTMX’s Market Performance
CTMX stock saw a decrease of -2.33% in the past week, with a monthly decline of -16.33% and a quarterly a decrease of 32.08%. The volatility ratio for the week is 6.83%, and the volatility levels for the last 30 days are 6.96% for CytomX Therapeutics Inc (CTMX). The simple moving average for the past 20 days is -1.11% for CTMX’s stock, with a 32.00% simple moving average for the past 200 days.
Analysts’ Opinion of CTMX
Many brokerage firms have already submitted their reports for CTMX stocks, with BMO Capital Markets repeating the rating for CTMX by listing it as a “Market Perform.” The predicted price for CTMX in the upcoming period, according to BMO Capital Markets is $2.60 based on the research report published on November 14, 2022 of the previous year 2022.
Wedbush, on the other hand, stated in their research note that they expect to see CTMX reach a price target of $2, previously predicting the price at $6. The rating they have provided for CTMX stocks is “Neutral” according to the report published on July 07th, 2022.
Piper Sandler gave a rating of “Neutral” to CTMX, setting the target price at $1.50 in the report published on July 07th of the previous year.
CTMX Trading at 7.04% from the 50-Day Moving Average
After a stumble in the market that brought CTMX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -26.44% of loss for the given period.
Volatility was left at 6.96%, however, over the last 30 days, the volatility rate increased by 6.83%, as shares sank -2.33% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +30.43% upper at present.
During the last 5 trading sessions, CTMX fell by -2.33%, which changed the moving average for the period of 200-days by +36.36% in comparison to the 20-day moving average, which settled at $2.12. In addition, CytomX Therapeutics Inc saw 35.48% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CTMX starting from McCarthy Sean A., who sale 20,223 shares at the price of $2.09 back on Mar 19 ’24. After this action, McCarthy Sean A. now owns 524,481 shares of CytomX Therapeutics Inc, valued at $42,175 using the latest closing price.
BELVIN MARCIA, the SVP, Chief Scientific Officer of CytomX Therapeutics Inc, sale 12,795 shares at $2.09 during a trade that took place back on Mar 19 ’24, which means that BELVIN MARCIA is holding 168,579 shares at $26,684 based on the most recent closing price.
Stock Fundamentals for CTMX
Current profitability levels for the company are sitting at:
- -0.06 for the present operating margin
- 0.95 for the gross margin
The net margin for CytomX Therapeutics Inc stands at 0.02. The total capital return value is set at -0.13.
Based on CytomX Therapeutics Inc (CTMX), the company’s capital structure generated -0.42 points at debt to capital in total, while cash flow to debt ratio is standing at -4.01. The debt to equity ratio resting at -0.29. The interest coverage ratio of the stock is 2.77.
Currently, EBITDA for the company is -4.31 million with net debt to EBITDA at 0.67. When we switch over and look at the enterprise to sales, we see a ratio of 1.37. The receivables turnover for the company is 29.49for trailing twelve months and the total asset turnover is 0.49. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.17.
Conclusion
In summary, CytomX Therapeutics Inc (CTMX) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
